Related references
Note: Only part of the references are listed.Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC
Benjamin Besse et al.
ONCOIMMUNOLOGY (2016)
Selection and expansion of natural killer cells for NK cell-based immunotherapy
Petra S. A. Becker et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Rationale for anti-CD137 cancer immunotherapy
Amani Makkouk et al.
EUROPEAN JOURNAL OF CANCER (2016)
The Helix-Loop-Helix Protein ID2 Governs NK Cell Fate by Tuning Their Sensitivity to Interleukin-15
Rebecca B. Delconte et al.
IMMUNITY (2016)
CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies
Annette Romanski et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2016)
CIS is a potent checkpoint in NK cell-mediated tumor immunity
Rebecca B. Delconte et al.
NATURE IMMUNOLOGY (2016)
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
Sebastien Viel et al.
SCIENCE SIGNALING (2016)
Repression of GSK3 restores NK cell cytotoxicity in AML patients
Reshmi Parameswaran et al.
NATURE COMMUNICATIONS (2016)
Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
Stephen J. Blake et al.
CANCER DISCOVERY (2016)
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
Sebastien Viel et al.
SCIENCE SIGNALING (2016)
Natural killer cell immunotherapy to target stem-like tumor cells
Steven K. Grossenbacher et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients
Jacek Nowak et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Challenges of cancer therapy with natural killer cells
Hans Klingemann
CYTOTHERAPY (2015)
A phase I/II trial of interleukin-15-stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors
Antonio Perez-Martinez et al.
CYTOTHERAPY (2015)
The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer
Zhenxin Wang et al.
IMMUNOLOGICAL INVESTIGATIONS (2015)
Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
Liyun Xu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
Immunosurveillance and therapy of multiple myeloma are CD226 dependent
Camille Guillerey et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Kevin C. Conlon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Cutting Edge: Identification and Characterization of Human Intrahepatic CD49a+ NK Cells
Nicole Marquardt et al.
JOURNAL OF IMMUNOLOGY (2015)
Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer
Naoyuki Sakamoto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection
Weiwen Deng et al.
SCIENCE (2015)
On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation
Alexander M. Lesokhin et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients
Michaela Semeraro et al.
Science Translational Medicine (2015)
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, 0X40, GITR, CD27, CD28, and ICOS
Miguel F. Sanmamed et al.
SEMINARS IN ONCOLOGY (2015)
DNAM-1 Expression Marks an Alternative Program of NK Cell Maturation
Ludovic Martinet et al.
CELL REPORTS (2015)
NKG2D Receptor and Its Ligands in Host Defense
Lewis L. Lanier
CANCER IMMUNOLOGY RESEARCH (2015)
Advantages and applications of CAR-expressing natural killer cells
Wolfgang Glienke et al.
FRONTIERS IN PHARMACOLOGY (2015)
Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis
Camille Guillerey et al.
ONCOIMMUNOLOGY (2015)
Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation
Nirali N. Shah et al.
BLOOD (2015)
Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies
Saar Gill et al.
IMMUNOLOGICAL REVIEWS (2015)
The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells
Bo Yuan Huang et al.
PLOS ONE (2015)
CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
Jianfeng Han et al.
SCIENTIFIC REPORTS (2015)
Balancing natural killer cell activation through paired receptors
Ludovic Martinet et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
Kurt Schönfeld et al.
MOLECULAR THERAPY (2014)
Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma
Jessica Rueff et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer Cells
Jeffrey W. Leong et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
Holbrook E. Kohrt et al.
BLOOD (2014)
Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15
Masaru Imamura et al.
BLOOD (2014)
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein
Veronika Bachanova et al.
BLOOD (2014)
Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor
Deepak Mittal et al.
CANCER RESEARCH (2014)
Effect of tumor cells and tumor microenvironment on NK-cell function
Massimo Vitale et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Interleukin-15 in the treatment of cancer
Thomas A. Waldmann
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Neha Korde et al.
HAEMATOLOGICA (2014)
The unconventional expression of IL-15 and its role in NK cell homeostasis
Nicholas D. Huntington
IMMUNOLOGY AND CELL BIOLOGY (2014)
被撤回的出版物: Targeting CD137 enhances the efficacy of cetuximab (Retracted article. See vol. 129, pg. 2595, 2019)
Holbrook E. Kohrt et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
CTLA-4 Is Expressed by Activated Mouse NK Cells and Inhibits NK Cell IFN-γ Production in Response to Mature Dendritic Cells
Ana Stojanovic et al.
JOURNAL OF IMMUNOLOGY (2014)
Cutting Edge: Salivary Gland NK Cells Develop Independently of Nfil3 in Steady-State
Victor S. Cortez et al.
JOURNAL OF IMMUNOLOGY (2014)
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
Jason R. Westin et al.
LANCET ONCOLOGY (2014)
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
Magdalena Paolino et al.
NATURE (2014)
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
Christopher J. Chan et al.
NATURE IMMUNOLOGY (2014)
The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells
Antoine Marais et al.
NATURE IMMUNOLOGY (2014)
Tissue-resident natural killer cells and their potential diversity
Dorothy K. Sojka et al.
SEMINARS IN IMMUNOLOGY (2014)
Clinical utility of natural killer cells in cancer therapy and transplantation
David A. Knorr et al.
SEMINARS IN IMMUNOLOGY (2014)
Clinical and immunological significance of HLA-E in stem cell transplantation and cancer
L. Wieten et al.
TISSUE ANTIGENS (2014)
Targeting Cancer-Derived Adenosine: New Therapeutic Approaches
Arabella Young et al.
CANCER DISCOVERY (2014)
Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
Ines Pires da Silva et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Improving the safety of cell therapy products by suicide gene transfer
Benjamin S. Jones et al.
Frontiers in Pharmacology (2014)
Are natural killer cells superior CAR drivers?
Hans Klingemann
ONCOIMMUNOLOGY (2014)
Regulation of Ligands for the NKG2D Activating Receptor
David H. Raulet et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
Rizwan Romee et al.
BLOOD (2013)
Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+T and NK cells and improves survival
Richard K. Yang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy
Q. Zhou et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab
Christian A. Gerdes et al.
CLINICAL CANCER RESEARCH (2013)
Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
Andres Wiernik et al.
CLINICAL CANCER RESEARCH (2013)
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Torsten Tonn et al.
CYTOTHERAPY (2013)
Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR
Noa Stanietsky et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells
Alexandre Iannello et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands
Laura Jardine et al.
LEUKEMIA & LYMPHOMA (2013)
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors
Paul A. Beavis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
CDK8-Mediated STAT1-S727 Phosphorylation Restrains NK Cell Cytotoxicity and Tumor Surveillance
Eva Maria Putz et al.
CELL REPORTS (2013)
Novel immune modulators used in hematology: impact on NK cells
Stephanie Krieg et al.
FRONTIERS IN IMMUNOLOGY (2013)
Innate lymphoid cells - a proposal for uniform nomenclature
Hergen Spits et al.
NATURE REVIEWS IMMUNOLOGY (2013)
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Norbert Vey et al.
BLOOD (2012)
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
Don M. Benson et al.
BLOOD (2012)
IL-2-or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients
Maria P. Roberti et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer
N. Steele et al.
BRITISH JOURNAL OF CANCER (2012)
Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor
Christiane Sahm et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Melanoma Cells Inhibit NK Cell Functions-Letter
Giuseppe Sconocchia et al.
CANCER RESEARCH (2012)
Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer
Javier Rodriguez et al.
EUROPEAN JOURNAL OF CANCER (2012)
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
Nidale Tarek et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression
Lucas E. Rossi et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
Michelle K. Gleason et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity
C. Kellner et al.
LEUKEMIA (2012)
被撤回的出版物: CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies (Retracted article. See vol. 134, pg. 658, 2019)
Holbrook E. Kohrt et al.
BLOOD (2011)
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
Antonio Curti et al.
BLOOD (2011)
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
Don M. Benson et al.
BLOOD (2011)
Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
Maria R. Parkhurst et al.
CLINICAL CANCER RESEARCH (2011)
Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation
Benjamin J. Schmiedel et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Bi-specific Aptamers Mediating Tumor Cell Lysis
Achim Boltz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
IL-10 Restricts Activation-Induced Death of NK Cells during Acute Murine Cytomegalovirus Infection
Maria A. Stacey et al.
JOURNAL OF IMMUNOLOGY (2011)
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
Nicolas F. Delahaye et al.
NATURE MEDICINE (2011)
CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells
Tina Baessler et al.
BLOOD (2010)
Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy
David C. Delgado et al.
CANCER RESEARCH (2010)
Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas
Luis F. Porrata et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2010)
NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia
Jeffrey E. Rubnitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
DNAM-1/CD155 Interactions Promote Cytokine and NK Cell-Mediated Suppression of Poorly Immunogenic Melanoma Metastases
Christopher J. Chan et al.
JOURNAL OF IMMUNOLOGY (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
Francois Romagne et al.
BLOOD (2009)
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells
Andreas Lundqvist et al.
BLOOD (2009)
HLA-E upregulation on IFN-γ-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT
S. Nguyen et al.
BONE MARROW TRANSPLANTATION (2009)
Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity
Xiangling Wang et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15Rα
Sophie Viaud et al.
PLOS ONE (2009)
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Noa Stanietsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: A prospective study
Luis F. Porrata et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Lei Wu et al.
CLINICAL CANCER RESEARCH (2008)
NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma
Esther Moga et al.
EXPERIMENTAL HEMATOLOGY (2008)
Developmental pathways that generate natural-killer-cell diversity in mice and humans
Nicholas D. Huntington et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Perforin-mediated target-cell death and immune homeostasis
Ilia Voskoboinik et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Functional subsets of mouse natural killer cells
Yoshihiro Hayakawa et al.
IMMUNOLOGICAL REVIEWS (2006)
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
Julie A. Bowles et al.
BLOOD (2006)
Self-tolerance of natural killer cells
David H. Raulet et al.
NATURE REVIEWS IMMUNOLOGY (2006)
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
EP von Strandmann et al.
BLOOD (2006)
CD4+-CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer
MJ Smyth et al.
JOURNAL OF IMMUNOLOGY (2006)
CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner
F Ghiringhelli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
JS Miller et al.
BLOOD (2005)
Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response
WL Gluck et al.
CLINICAL CANCER RESEARCH (2004)
Cutting edge: CD96 (Tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155)
A Fuchs et al.
JOURNAL OF IMMUNOLOGY (2004)
The beneficial role of inhibitory KIR genes of HLA class INK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD
A Bishara et al.
TISSUE ANTIGENS (2004)
Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format
LS Shahied et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
IL-10 stimulatory effects on human NK cells explored by gene profile analysis
S Mocellin et al.
GENES AND IMMUNITY (2004)
IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial
LJ Burns et al.
BONE MARROW TRANSPLANTATION (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants
SM Davies et al.
BLOOD (2002)
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
V Groh et al.
NATURE (2002)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
FE Davies et al.
BLOOD (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
